The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.

Launched by BISPEBJERG HOSPITAL · Mar 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how a hormone called glucagon affects blood flow in the kidneys using MRI technology. Glucagon helps manage blood sugar levels and can impact kidney function, which is particularly important for people with conditions like type 2 diabetes. The researchers want to learn more about how glucagon influences blood flow in different parts of the kidneys and whether this is connected to the way glucagon interacts with specific receptors.

The study will involve 10 healthy men aged 20 to 60 years. Participants will take part in three test days where they will receive either glucagon, glucagon combined with another medication, or a placebo (an inactive substance). To be eligible, participants need to be in good health, with normal blood test results, and must provide informed consent. Those with certain health issues, such as kidney problems, liver disease, or who have taken specific medications recently, will not be able to participate. Throughout the trial, researchers will measure kidney function and blood flow to better understand glucagon's effects.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Normal health confirmed through; Interview and Medical examination
• • Normal values with respect to blood concentrations of fasting plasma glucose, fasting plasma total cholesterol, fasting triglycerides, HDL, LDL, creatinine, liver function tests, and electrolytes
• • Informed consent
• Exclusion Criteria:
• • Immunosuppressive treatment in the previous 12 months
• • Alcohol abuse
• • Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists, which, in the opinion of the principal investigator, may interfere with glucose metabolism
• • Use of lithium
• • Medical treatment that affects insulin secretion or the renin-angiotensin-aldosterone system
• • Liver disease (ALT \> 2x normal value)
• • Renal impairment (serum creatinine \> 130 µM and/or albuminuria)
• • Individuals with severe claustrophobia
• • Individuals with MR-incompatible foreign bodies
• • Individuals with hypertension